121 related articles for article (PubMed ID: 15551349)
1. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68).
Machida S; Saga Y; Takei Y; Mizuno I; Takayama T; Kohno T; Konno R; Ohwada M; Suzuki M
Int J Cancer; 2005 Mar; 114(2):224-9. PubMed ID: 15551349
[TBL] [Abstract][Full Text] [Related]
2. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis.
Tokuyama J; Kubota T; Saikawa Y; Yoshida M; Furukawa T; Otani Y; Kumai K; Kitajima M
Anticancer Res; 2005; 25(1A):17-22. PubMed ID: 15816514
[TBL] [Abstract][Full Text] [Related]
4. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
7. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.
Griffin RJ; Williams BW; Wild R; Cherrington JM; Park H; Song CW
Cancer Res; 2002 Mar; 62(6):1702-6. PubMed ID: 11912143
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
11. TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
Yorozuya K; Kubota T; Watanabe M; Hasegawa H; Ozawa S; Kitajima M; Chikahisa LM; Yamada Y
Oncol Rep; 2005 Sep; 14(3):677-82. PubMed ID: 16077974
[TBL] [Abstract][Full Text] [Related]
12. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms.
Shaheen RM; Tseng WW; Davis DW; Liu W; Reinmuth N; Vellagas R; Wieczorek AA; Ogura Y; McConkey DJ; Drazan KE; Bucana CD; McMahon G; Ellis LM
Cancer Res; 2001 Feb; 61(4):1464-8. PubMed ID: 11245452
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice.
Takei Y; Saga Y; Mizukami H; Takayama T; Ohwada M; Ozawa K; Suzuki M
Mol Cancer Ther; 2008 Mar; 7(3):704-11. PubMed ID: 18347155
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
[TBL] [Abstract][Full Text] [Related]
16. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
18. Combined antiangiogenic and immune therapy of prostate cancer.
Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
[TBL] [Abstract][Full Text] [Related]
19. [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Jiang XT; Tao HQ; Zou SC
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):335-7. PubMed ID: 16886118
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer.
Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K
Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]